Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts
Roberto Rossotti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Antonella d’Arminio Monforte(University of Milan), Alessandro Soria(University of Milano-Bicocca), Letizia Marinaro(University of Turin), Antonella Cingolani(Agostino Gemelli University Polyclinic), Annalisa Saracino(University of Bari Aldo Moro), Cristina Mussini(University of Modena and Reggio Emilia), Sergio Lo Caputo(Ospedale Santa Maria Annunziata), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Stefano Bonora(Ospedale Amedeo di Savoia), Alessandro Tavelli
Cited by 2
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
|The Lancet|2014|930
Female gender is associated with long COVID syndrome: a prospective cohort study
|Clinical Microbiology and Infection|2021|656